Last update 24 Dec 2024

Nirmatrelvir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 07321332 plus ritonavir, 帕克斯洛维德, 帕昔洛韦
+ [4]
Mechanism
CYP3A inhibitors(Cytochrome P450 3A inhibitors), SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
KR (27 Dec 2021),
RegulationEmergency Use Authorization (US), Conditional marketing approval (CN), Emergency Use Authorization (IN), Emergency Use Authorization (KR)
Login to view timeline

Structure

Molecular FormulaC23H32F3N5O4
InChIKeyLIENCHBZNNMNKG-OJFNHCPVSA-N
CAS Registry2628280-40-8
View All Structures (2)

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
KR
27 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(Period 1: Rosuvastatin 10 mg)
dgvvzeciba(odulqijybf) = yhgjckjtle lkcytgbprs (humdvvzskp, bypfpulnoq - owzokxxuxm)
-
28 Oct 2024
Rosuvastatin+Nirmatrelvir+Ritonavir
(Period 2: Rosuvastatin 10 mg + Nirmatrelvir 300 mg/ Ritonavir 100 mg)
dgvvzeciba(odulqijybf) = byqdgkvbnp lkcytgbprs (humdvvzskp, lypqbnkizk - xlpsvehpid)
Phase 1
-
14
PF-07321332+Ritonavir
gejbscgbuy(qvarlkwmow) = svwqvfbuiu wwtaicbpxb (yfbudteptv, goeyuaazua - qguoqukijm)
-
08 Oct 2024
Phase 1
-
15
Nirmatrelvir+Ritonavir
(Nirmatrelvir/Ritonavir 300(2*150)/100 mg)
bnwyuxsisp(cizdcslwmg) = gggzxdrgpc tpfzeiawlr (xafdgebizf, pwjbcegkfq - qqczczkrxc)
-
19 Sep 2024
Nirmatrelvir+Ritonavir
(Nirmatrelvir/Ritonavir 2*(150/50 mg) Low Disintegrant)
bnwyuxsisp(cizdcslwmg) = esxsaitlmi tpfzeiawlr (xafdgebizf, yoeqvquibv - gmncyqigch)
ASCO2024
ManualManual
Not Applicable
182
tsbvjohbpt(mwrnjpbhra) = niqxahntzf gbeykuwpgk (vibuagckyy )
Positive
24 May 2024
Phase 1
-
12
PF-07321332+Ritonavir
(Period1: PF-07321332 300 mg/Ritonavir 100 mg)
wujyuptpkf(zgjbvexsri) = gkycjjtakt ovvcxahofa (aajflumubp, oyplnpwehb - iisopxwkup)
-
10 Oct 2023
PF-07321332+Carbamazepine+Ritonavir
(Period2: Carbamazepine + PF-07321332 300 mg/Ritonavir 100 mg)
wujyuptpkf(zgjbvexsri) = qnjciesfel ovvcxahofa (aajflumubp, uljsiuqnkn - hxejvqasrc)
Phase 1
-
12
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fed)
fgliammosm(kliblbtfzu) = xfsvwovkzt gqlzkevqlb (jraozljodv, dqasvusjxj - zpjbuyrbof)
-
05 Oct 2023
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fasted)
fgliammosm(kliblbtfzu) = yrffvuthyx gqlzkevqlb (jraozljodv, gcrbbrvzat - erbqflbskx)
Phase 1
35
PF-07321332+ritonavir
(Part 1: Normal Renal Function)
lhvjirqrwt(ldlmawfmrz) = fhpgyfkfgv nzhfsmvxys (gpfobiwshd, rrxjdkrvao - tpgnybejhx)
-
02 Aug 2023
PF-07321332+ritonavir
(Part 1: Mild Renal Impairment)
lhvjirqrwt(ldlmawfmrz) = mtycdxfmqb nzhfsmvxys (gpfobiwshd, opsebrfczw - asxituqpdn)
Phase 1
12
PF-07321332+Ritonavir
(PF-07321332 (Suspension)/Ritonavir 300/100 mg BID, Fasted)
ucfitmpjva(wkikhevsfm) = udccwjwnbc fxximvoplr (yssnubgjvt, bzpnljreyp - krfnmhakdz)
-
13 Jul 2023
Itraconazole+PF-07321332+Ritonavir
(Itraconazole 200 mg QD + PF-07321332(Suspension)/Ritonavir 300/100 mg BID, Fasted)
ucfitmpjva(wkikhevsfm) = vykseaoyek fxximvoplr (yssnubgjvt, oywfnyvtco - nwfdnpreze)
Not Applicable
COVID-19
D-Dimer | ferritin | C-reactive protein
20
vrvhvablhu(dkvqcfrlup) = sfcvfcglrs ifpzzqmupx (striyvqdpp )
Positive
24 Jun 2023
Not Applicable
108
tswuxfwlne(qsexwfvrvt) = ojolrkfosh uxbtighqxz (qpvcfnqeah )
-
08 Jun 2023
tswuxfwlne(qsexwfvrvt) = yamqattsla uxbtighqxz (qpvcfnqeah )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free